CWT Versus AT on Selected Cardiovascular Indices and Functional Capacity in Patients With Ischemic Cardiomyopathy.

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05674955
Collaborator
(none)
60
3
1.7

Study Details

Study Description

Brief Summary

To compare between the effect of circuit weight and aerobic training on selected cardiovascular indices and functional capacity in patients with ischemic cardiomyopathy.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Circuit weight versus aerobic training
N/A

Detailed Description

Ischemic cardiomyopathy (ICM) is a term that refers to the heart's decreased ability to pump blood properly due to myocardial damage brought upon by ischemia. Ischemic cardiomyopathy has a spectrum of clinical changes which eventually leads to congestive heart failure (CHF). Initially, there is a reversible loss of cardiac contractile function because of decreased oxygen supply to the heart muscle; however, when there is ischemia for a prolonged period, there is irreversible cardiac muscle damage resulting in cardiac remodeling. Remodeling is primarily achieved by myocardial fibrosis which results in decreased cardiac function, arrhythmia, and possible cardiac conduction system impairment. In ischemic cardiomyopathy, there is a significant impairment of the left ventricular systolic function, with a left ventricular ejection fraction (LVEF) less than 40% (Bhandari et al., 2021).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
3 groups of ischemic cardiomyopathy patients. 1st group receive circuit weight training. 2nd group receive aerobic. 3rd group receive medications3 groups of ischemic cardiomyopathy patients. 1st group receive circuit weight training. 2nd group receive aerobic. 3rd group receive medications
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Circuit Weight Versus Aerobic Training on Selected Cardiovascular Indices and Functional Capacity in Patients With Ischemic Cardiomyopathy.
Anticipated Study Start Date :
Dec 30, 2022
Anticipated Primary Completion Date :
Feb 20, 2023
Anticipated Study Completion Date :
Feb 20, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Circuit weight group

Diagnostic Test: Circuit weight versus aerobic training
Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014) B- Aerobic training: This mode of exercise will be conducted for study group B as follows: Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises. Frequency: Three times / week (Nishi et al., 2011). C-Traditional medical treatment: This treatment will be conducted for all group A, B and C.

Experimental: Aerobic group

Diagnostic Test: Circuit weight versus aerobic training
Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014) B- Aerobic training: This mode of exercise will be conducted for study group B as follows: Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises. Frequency: Three times / week (Nishi et al., 2011). C-Traditional medical treatment: This treatment will be conducted for all group A, B and C.

Experimental: Control Group

Diagnostic Test: Circuit weight versus aerobic training
Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014) B- Aerobic training: This mode of exercise will be conducted for study group B as follows: Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises. Frequency: Three times / week (Nishi et al., 2011). C-Traditional medical treatment: This treatment will be conducted for all group A, B and C.

Outcome Measures

Primary Outcome Measures

  1. Ejection fraction [2 months]

    Will be measured by precentge

Secondary Outcome Measures

  1. Blood pressure [2 months]

    Will be measured by mmhg

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 55 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Sixty male patients with ischemic cardiomyopathy as a result of a recent acute myocardial infarction event (≤2 months) with 40%<LVEF<50%.

  • They are functionally classified as class II according to New York Heart Association (NYHA).

  • Their age will be ranged from 45 to 55 years old.

  • Their BMI will be ranged from 25 to 29.9 kg/m².

  • They will have good mentality.

Exclusion Criteria:
  • Recurrent coronary heart disease.

  • Severe valvular diseases.

  • Underlying pulmonary disease (aspiration pneumonia, chronic obstructive pulmonary disease, pneumothorax, etc.).

  • Inability to ambulate owing to physical problems (paresis induced by cerebral stroke, spinal cord injury, amputation, severe pain, dyspnea, etc.).

  • muskloskletal problems (e.g. severe osteoarthritis or ankylosing spondylitis).

  • Impaired cognitive function (vascular dementia, Alzheimer's dementia, other psychological disease, etc.)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Samira Shukrey Shaffik Eshak, Domenstrator, Cairo University
ClinicalTrials.gov Identifier:
NCT05674955
Other Study ID Numbers:
  • Cw versus AT in cardiomyopathy
First Posted:
Jan 9, 2023
Last Update Posted:
Jan 9, 2023
Last Verified:
Dec 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 9, 2023